Skip to content

Ayurvedic Intervention For Painful Menses

An open labelled randomised controlled clinical study to evaluate the efficacy of Shoolaprashamana Mahakashaya phanta versus Drotaverine in Kashtartava (Dysmenorrhea) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094741
Enrollment
60
Registered
2025-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified

Interventions

None listed

Sponsors

Shri Dhanwantry Ayurvedic College and Hospital
Lead Sponsor
Dr Anuradha Maganti
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: H/O Painful menstruation and pain few days prior to menstruation for atleast three consecutive cycle Age group of 15-49 year Patient having moderate to severe pain acc to MRC grading recommended by WHO Patient suffering from any type of menstrual pain premenstrual pain and average bleeding during periods periods that persisted for 3 months prior to the study will be included Patients with fibroids less than 3cm who had secondary dysmenorrhoea without menorrhagia Endometriosis Adenomyosis with regular periods and average bleeding during periods that persisted for 3 months prior to the study will be included

Exclusion criteria

Exclusion criteria: Congenital anomalies Patient on hormonal therapy Pelvic Inflammatory Disease Endometrial Hyperplasia Patients who are taking oral contraceptive pill IUCD suffered from chronic general illness pregnant women lactating women Uterine fibroids of size greater than 3cm with menorrhagia Patient having irregular periods Abnormal Uterine Bleeding Menstrual Pain associated with Menorrhagia and Metrorrhagia Ovarian Cyst greater than 6cm Known cases of systemic illness like cancer tuberculosis diabetes etc Known cases of cardiovascular hematologic hepatic gastrointestinal renal pulmonary endocrinologic neurologic disease Known cases of hypersensitivity or contraindication to drotaverine

Design outcomes

Primary

MeasureTime frame
Reduction in scoring of VAS and MRS grading 80% reductionTimepoint: Baseline 1st 2nd and 3rd Menstrual Cycle

Secondary

MeasureTime frame
Reduction in associated systemic symptoms Nausea Vomiting Headache Fatigue DiarrhoeaTimepoint: Baseline and 3rd Menstrual Cycle

Countries

India

Contacts

Public ContactNeetika

Shri Dhanwantry Ayurvedic College and Hospital

dranuradha98@gmail.com9043940396

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026